Celalettin Ustun to Middle Aged
This is a "connection" page, showing publications Celalettin Ustun has written about Middle Aged.
Connection Strength
0.273
-
Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. Int J Lab Hematol. 2021 02; 43(1):e19-e25.
Score: 0.069
-
Biosimilar infliximab administration for the management of acute graft-versus-host disease. J Oncol Pharm Pract. 2020 Dec; 26(8):2047-2051.
Score: 0.067
-
DLBCL After Allogeneic HCT in a Patient With Transformed DLBCL: Does It Matter Whether Relapse or PTLD? Clin Lymphoma Myeloma Leuk. 2020 04; 20(4):264-266.
Score: 0.065
-
Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. JAMA Oncol. 2022 Mar 01; 8(3):404-411.
Score: 0.019
-
Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Adv. 2018 11 13; 2(21):2922-2936.
Score: 0.015
-
Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2017 Jun; 23(6):971-979.
Score: 0.013
-
Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant. 2017 May; 23(5):767-775.
Score: 0.013
-
Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant. 2014 Feb; 20(2):202-8.
Score: 0.011